Why hasn't anyone applied for cancer drug status for fenbendazole or ivermectin?
In the U.S., such a new drug would have at least a 3-year market exclusivity period, potentially generating over $10 billion in revenue.
undefined subscriptions will be displayed on your profile (edit)
Skip for now
For your security, we need to re-authenticate you.
Click the link we sent to , or click here to sign in.
Why hasn't anyone applied for cancer drug status for fenbendazole or ivermectin?
In the U.S., such a new drug would have at least a 3-year market exclusivity period, potentially generating over $10 billion in revenue.